Marker Therapeutics, Inc.
MRKR
$1.43
$0.021.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -10.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -10.50% | |||
| Cost of Revenue | 32.79% | -8.74% | |||
| Gross Profit | -174.02% | 6.78% | |||
| SG&A Expenses | 45.26% | -17.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 36.32% | -11.35% | |||
| Operating Income | -116.16% | 11.83% | |||
| Income Before Tax | -85.02% | 14.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -86.67% | 14.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -86.67% | 14.78% | |||
| EBIT | -116.16% | 11.83% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -87.05% | 26.24% | |||
| Normalized Basic EPS | -85.41% | 25.50% | |||
| EPS Diluted | -87.05% | 26.67% | |||
| Normalized Diluted EPS | -85.41% | 25.50% | |||
| Average Basic Shares Outstanding | -0.23% | 15.52% | |||
| Average Diluted Shares Outstanding | -0.23% | 15.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||